Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas

Annals of Surgery

Volumn 243, Issue 3, 2006, Pages 334-340

  Driessen, Ann ^a   Landuyt, Willy ^b   Pastorekova, Sylvia ^c   Moons, Johnny ^b   Goethals, Laurence ^b   Haustermans, Karin ^b   Nafteux, Philippe ^b   Penninckx, Freddy ^b   Geboes, Karel ^b   Lerut, Toni ^b   Ectors, Nadine ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; PARAFFIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CARDIA CARCINOMA; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TUMOR LOCALIZATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644638219     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000201452.09591.f3     Document Type: Article

References (54)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer. 2001;37(suppl):4-66.
2. Erratum appears in Eur J Cancer. 2001;39:848.
3. Ohno S, Tomisaki S, Oiwa H, et al. Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. J Am Coll Surg. 1995;180:577-582.
4. Maehara Y, Moriguchi S, Kakeji Y, et al. Prognostic factors in adenocarcinoma in the upper one-third of the stomach. Surg Gynecol Obstet. 1991;173:223-226.
5. Jones DR, Detterbeck FC, Egan TM, et al. Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus. Ann Thorac Surg. 1997;64:185-191.
6. Allum W, Cunningham D, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomized, controlled trial (the MAGIC trial, ISRCTN 93793971) [Abstract 998]. Proc Am Soc Clin Oncol. 2003;22:249.
7. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.
8. Skoropad VY, Berdov BA, Zagrebin VM. Preoperative radiotherapy in combination with metronidazole for respectable gastric cancer: long-term results of a phase 2 study. Eur J Surg Oncol. 2003;29:166-170.
9. Grau J, Martin M, Fuster J, et al. Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer. J Surg Oncol. 2003;82:234-240.
10. Wouters BG, Weppler SA, Koritzinsky M, et al. Hypoxia as a target for combined modality treatments. Eur J Cancer. 2002;38:240-257.
11. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumor invasion and metastasis. Eur J Cancer. 2000;36:1621-1630.
12. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 1996; 379:88-91.
13. Semenza GL. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev. 2000;9:59-65.
14. Wykoff CC, Beasley NJP, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60: 7075-7083.
15. Forsythe JA, Jiang B-H, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604-4613.
16. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
17. Ploüet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J. 1989;8:3801-3807.
18. Pastorek J, Pastorekova S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 1994;9:2877-2888.
19. Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem. 1995;64:375-401.
20. Zavada J, Zavadova Z, Pastorek J, et al. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer. 2000;82:1808-1813.
21. Saarnio J, Parkkila S, Parkkila A-K, et al. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J Histochem Cytochem. 1998;46:497-504.
22. Bartasova M, Parkkila S, Pohlodek K, et al. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J Pathol. 2002;197:314-321.
23. Beasley NJP, Wykoff CC, Watson PH, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 2001;61:5262-5267.
24. Liao SY, Brewer C, Zavada J, et al. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol. 1994;145:598-609.
25. Liao S-Y, Aurelio ON, Jan K, et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 1997;57:2827-2831.
26. Swinson DEB, Jones JL, Richardson D, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol. 2003;21:473-482.
27. Turner JR, Odze RD, Crum CP, et al. MN antigen expression in normal, preneoplastic and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Hum Pathol. 1997;28:740-744.
28. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors, 6th ed. New York: Wiley-Liss, 2002.
29. Wittekind C, Henson DE, Hutter RVP, et al. TNM Supplement: A Commentary on Uniform Use, 2nd ed. New York: Wiley-Liss, 2001.
30. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
31. Pastorekova S, Zavadova Z, Kostal M, et al. A novel quasi-viral agent, MaTu, is a two-component system. Virology. 1992;187:620-626.
32. Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001;19:3660-3668.
33. Baillie R, Carlile J, Pendleton N, et al. Prognostic value of vascularity and vascular endothelial growth factor in non-small cell lung cancer. J Clin Pathol. 2001;54:116-120.
34. Vermeulen PB, Libura M, Libura J, et al. Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. Breast Cancer Res Treatment. 1997;42:165-172.
35. Gundersen HJ, Bendtsen TF, Korbo L, et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS. 1988;96:379-394.
36. Voordeckers M, Vinh-Hung V, Van de Steene J, et al. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol. 2004;70:225-230.
37. Driessen A, Winnepenninckx V, Filez L, et al. Microvessel density and VEGF expression correlate with the known prognostic features of intestinal type carcinoma, compared to diffuse type carcinoma in oesophageal, proximal and distal cancer. Gut. 2001;49(suppl III):A2718.
38. Driessen A, Landuyt W, Goethals L, et al. Upregulated expression of VEGF and CAIX correlate with the vascular metastasis pattern of intestinal type carcinoma. Gastroenterology. 2003;124(suppl 1):A184.
39. Zavada J, Zavadova Z, Pastorekova S, et al. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer. 1993;54:268-274.
40. Pastorekova S, Parkkila S, Parkkila A-K, et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology. 1997; 112:398-408.
41. Saarnio J, Parkkila S, Parkkila A-K, et al. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J Histochem Cytochem. 1998;46:497-504.
42. Zavada J, Zavadova Z, Pastorek J, et al. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer. 2000;82:1808-1813.
43. Helmlinger G, Sckell A, Dellian M, et al. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res. 2002;8:1284-1291.
44. Stubbs M, McSheehy PMJ, Griffiths JR, et al. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today. 2000;6:15-19.
45. Kivela AJ, Parkkila S, Saarnio J, et al. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem Cell Biol. 2000;114:197-204.
46. Saarnio J, Parkkila S, Parkkila A-K, et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol. 1998;153:279-285.
47. Saarnio J, Parkkila S, Parkkila A-K, et al. Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours. J Hepatol. 2001;35:643-649.
48. Ivanov S, Liao S-H, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic arihydrases in human cancer. Am J Pathol. 2001;158:905-919.
49. Leppilampi M, Saarnio J, Karttunen TJ, et al. Carbonic anhydrase isozyme IX and XII in gastric tumors. World J Gastroenterol. 2003;9:1398-1403.
50. Takahashi Y, Cleary KR, Mai M, et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res. 1996;2:1679-1684.
51. Saito H, Tsujitani S, Kondo A, et al. Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma. Surgery. 1999;125:195-201.
52. Carneiro F, Sobrinho-Simoes M. Metastatic pattern of gastric carcinoma. Hum Pathol. 1996;27:213-214.
53. Mori M, Sakaguchi H, Akazawa K, et al. Correlation between metastatic site, histological type, and serum tumor markers of gastric carcinoma. Hum Pathol. 1995;26:504-508.
54. Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett. 2003;13:1005-1009.